Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01217034
Other study ID # JLOG 1001 trial
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received October 2, 2010
Last updated October 30, 2017
Start date October 2010
Est. completion date March 2018

Study information

Verified date October 2017
Source Japan Liver Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical resection or percutaneous ablation therapy.


Description:

TACE with sorafenib Group

Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.

Control group

TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.

The treatment regimen will be continued until untreatable progression which is defined as follows:

- Child-Pugh grade C

- Tumor growth (125 percent from baseline status)

- Vascular invasion(Vp3,Vp4)

- Extra hepatic spread which size is more than 10mm


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 228
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Patients aged 20 Years or over

2. Patients who were fully informed of the study beforehand and signed the informed consent to participate in the study.

3. Patients who are expected to live more than 12 weeks.

4. Patients diagnosed with typical HCC by biopsy,cytology, or diagnostic imaging such as dynamic CT(MRI).Typical HCC is defined by AASLD criteria.

5. Patients in whom complete resection of the tumor by hepatectomy or complete tumor necrosis by local tumor necrosis therapy(RFA) cannot be expected to succeed.

6. Patients with tumors which are confirmed to the liver and can be treated by TACE(the maximum diameter equal to or less than 10cm,and the maximum number of nodule equal to or less than 10).

7. Patients with viable and measurable target lesion.

8. patients with no or one history of TACE therapy.

9. patients with an ECOG PS(Performance Status) Score of 0 or 1.

10. patients with Child-Pugh class A.

11. Patients with laboratory values that meet the following criteria:

1. Hemoglobin = 8.5 g/dl

2. Granulocytes = 1500/mm3

3. Platelet count = 50,000 /mm3

4. Total serum bilirubin = 3 mg/dl

5. AST and ALT = 6 times upper limits of normal

6. Serum creatinine = 1.5 times upper limits of normal

Exclusion Criteria:

1. History of malignant tumor, excluding the following cases:

1. Curatively treated early stage cancer with a low risk of recurrence ,such as carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumor, and early gastric cancer.

2. Malignant tumor that was curatively treated more than 3 years prior to study entry and has not recurred since then

2. Cardiac disease that meet any of the following criteria:

1. NYHA Class III or higher congestive heart failure

2. History of symptomatic coronary artery disease or myocardial infarction within 6 months before enrollment

3. Arrhythmia requiring control by antiarrhythmic drugs such as beta-blockers or digoxin

3. Serious and active infection, except for HBV and HCV

4. History of HIV infection

5. Renal dialysis

6. Diffuse tumor lesion

7. Extrahepatic metastasis

8. Vascular invasion

9. Intracranial tumor

10. Preexisting or history of hepatic encephalopathy

11. Clinically uncontrolled ascites or pleural effusion

12. Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment

13. Esophageal and/or gastric varices which has high risk of bleeding

14. History of thrombosis and/or embolism within 6 months of the start of treatment

15. History of receiving any of the following therapies:

1. Systemic chemotherapy for advanced HCC(including sorafenib therapy)

2. Local therapy, such as radiofrequency ablation, TACE, or hepatic arterial infusion within 3 months of the start of treatment

3. Current treatment with CYP3A4 inducing agents

4. Invasive surgery within 4 weeks of the start of treatment

5. History of allogenic transplantation

6. History of bone marrow transplant or haemopoietic stem cell transplant within 4 weeks of the start of this study

16. Unable to take oral medications

17. Gastrointestinal problems that may affect absorption or pharmacokinetics of the study drugs

18. Use of drugs that may affect absorption or pharmacokinetics of the study drugs

19. Concurrent disease or disability that may affect evaluation of the effects of the study drugs

20. Enrollment in another study within 4 weeks of study entry

21. Female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant

22. Risk of allergic reactions to the study drugs

23. Drug abuse or other physical, psychological , or social problems that may interfere with the participation in the study or evaluation of study results

24. Any condition that could jeopardize the safety of the patient or their compliance in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TACE with sorafenib
Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
Procedure:
TACE alone
TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.

Locations

Country Name City State
Japan Kinki University Hospital Osaka-Sayama Osaka

Sponsors (1)

Lead Sponsor Collaborator
Japan Liver Oncology Group

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival Patients will be evaluated for these endpoints every 8 weeks every 8 week
Primary Overall Survival The overall survival is defined as time from randomization to death due to any cause, and will be evaluated every 8 weeks in the protocol treatment, and every one year in the follow-up period,respectively. every 8 week
Secondary Time To Progression Time to progression is defined as time from randomization to radiological progression and will be evaluated every 8 week. every 8 weeks
Secondary Objective Response Rate Objective Response Rate is defined as best response 4week after TACE
Secondary Tumor markers Change of tumor markers every 4 weeks
Secondary Safety Number of participants with adverse events as a measure of safety and tolerability(According to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) every 4 weeks
Secondary Time To Untreatable Progression(TTUP) Time to untreatable progression is defined as time from randomization to untreatable progression and will be evaluated every 8 week. every 8 week till untreatable progression, assessed up to 100 months
Secondary Time to Child-Pugh C Time to Child-Pugh C is defined as time from randomization to Child-Pugh C and will be evaluated every 8 week. every 8 week till liver deterioration to Child-Pugh C, assessed up to 100 months
Secondary Time to intrahepatic tumor progression Time to intrahepatic tumor progression is defined as time from randomization to intrahepatic tumor progression and will be evaluated every 8 week. every 8 week till intrahepatic tumor progression, assessed up to 100 months
Secondary Time to vascular invasion Time to vascular invasion is defined as time from randomization to vascular invasion and will be evaluated every 8 week. every 8 week till vascular invasion, assessed up to 100 months
Secondary Time to Extrahepatic spread Time to extrahepatic spread is defined as time from randomization to extrahepatic spread and will be evaluated every 8 week. every 8 week till extrahepatic spread, assessed up to 100 months
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2